Institutional ownership in Akebia Therapeutics, Inc. accounts for approximately 34 to 37 percent of the company's total outstanding shares, with hundreds of professional investment firms, mutual fund complexes, and asset management trusts holding stakes. Prominent institutional holders include major global asset managers like BlackRock, along with various specialized healthcare funds and quantitative trading groups. The remaining equity distribution is split between corporate insiders and individual retail investors. Tracking institutional accumulation or liquidation trends helps market participants gauge professional sentiment regarding the biotechnology firm's financial stability and therapeutic pipeline potential.